Daniel Anton de Boer
CIK: 0002117546
Transaction Breakdown
Open Market Buys (P)3 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PRQR
ProQR Therapeutics N.V.
DirectorOfficer
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jul 31, 2026PRQR
ProQR Therapeutics N.V.
Purchase(P)Direct200K shares at avg. $1.77$354K - Jul 9, 2026PRQR
ProQR Therapeutics N.V.
Purchase(P)Direct150K shares at avg. $1.74$261K - Jul 7, 2026PRQR
ProQR Therapeutics N.V.
Purchase(P)Direct150K shares at avg. $1.59$239K
1-3 of 3 transactions
About de Boer Daniel Anton
de Boer Daniel Anton (SEC CIK 0002117546) files insider reports with the SEC as Chief Executive Officer of ProQR Therapeutics N.V. (PRQR).
Signal8 holds 4 ownership filings by de Boer Daniel Anton (1 Form 3, 3 Form 4), filed between Mar 18, 2026 and Aug 3, 2026. Those filings report 3 transactions, from Jul 7, 2026 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on de Boer Daniel Anton's filings is in LEIDEN.
Recent filings by de Boer Daniel Anton
Other insiders filing for ProQR Therapeutics N.V. (PRQR)
- Filius Bart, Director
- Hinsch Gylvin Lykke, Director
- Valerio Domenico, Director
- Platenburg Gerardus Johannes, Chief Scientific Officer
- Maier Martin Alexander, Director
- Lawton Alison Frances, Director